In 2009, a remarkable partnership started with an unsolicited email and a “cold call.”
Ten years later, Rockville, Maryland’s Sanaria and the Bioko Island Malaria Elimination Project (BIMEP) consortium won the P3 Impact Award from a pool of nearly 2,000 applicants, marking a milestone for a unique and remarkable global health consortium that’s turning the tide in the global fight against malaria.
Image: http://www.biohealthcapital.com
The COVID-19 pandemic has caused— and will continue to cause—much uncertainty in the worldwide financial markets. We expect to see substantial declines in the coming months in the number and aggregate dollar value of venture financings, similar to the declines during the dot-com crash in the early 2000s and during the 2008 financial crisis.
We are living and working through a period in human history when scientific leadership and knowledge are crucial for our nation, our organization and ourselves. It is a time for us to bring to the fore the focus on this most critical of human capabilities.
As you know, against the backdrop of the profound challenges we face as an industry – and now overlaid by the additional impact of COVID-19 – BIO has conducted a search for a new President and CEO. On behalf of the Executive Committee of the BIO Board of Directors, I am delighted to announce that we have appointed Dr. Michelle McMurry-Heath to lead BIO at this pivotal moment in our organization’s history, effective June 1, 2020.
Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led the financing round, which is just the latest accomplishment for the clinical-stage biotechnology company that launched in 2006.
PITTSBURGH, May 14, 2020 /PRNewswire/ — Net Health, a premier provider of cloud-based Electronic Health Record (EHR) software for specialized care settings, today announced that it has acquired Tissue Analytics, a pioneering developer of automated mobile wound and skin imaging and predictive analytics solutions. The acquisition of Tissue Analytics expands Net Health’s leadership position within the wound care market, and for all customers, will accelerate the delivery of next generation wound care technology solutions, including predictive analytics. Net Health is a portfolio company of The Carlyle Group, Level Equity, and Silversmith Capital Partners. Silversmith invested additional equity to support the acquisition of Tissue Analytics.
WASHINGTON — Michelle McMurry-Heath doesn’t talk about biotech the way her peers do.
Where other executives and experts might bring up “access,” and “reimbursement,” McMurry-Heath talks about fairness and ethics.
Image: Michelle McMurry-Heath has been named the new CEO of BIO.
The Trump administration has chosen their drug and vaccine development czar to head up the R&D side of the Covid-19 attack plan, but it’s not Elias Zerhouni.
While Zerhouni — the ex-NIH and ex-Sanofi vet — figured in the headlines as the lead candidate for that spot, Politico and other news outlets are reporting that the administration will tap ex-GSK exec Moncef Slaoui for that role.
Image: https://www.flickr.com/photos/mdgovpics/31274821010/
The Center for Innovative Technology (CIT) office building complex in Herndon has sold for $47.35 million, Gov. Ralph Northam announced Thursday.
The Virginia Department of General Services (DGS) sold the property Thursday to affiliates of Chicago-based Origami Capital Partners LLC and Timberline Real Estate Partners in a transaction that closed Thursday. Located at 2214 Rock Hill Road, the 149,000-square foot building sits on 26 acres located approximately 3 miles from Washington Dulles International Airport. The complex housed the CIT, the Northern Virginia Technology Council and private technology firms.
Image: Former Center for Innovative Technology building in Herndon. Photo courtesy Fairfax County Economic Development Authority.
The lack of treatment options for COVID-19 patients, potential promise in repurposing drugs, and controversy surrounding the anti-malarial drug hydroxychloroquine have created a storm of questions about the drug’s efficacy that the National Institute of Allergy and Infectious Diseases (NIAID) is ready to answer. To do that, the organization is sponsoring a large randomized, controlled clinical trial to determine whether hydroxychloroquine, given in combination with the antibiotic azithromycin, can prevent hospitalization and death due to COVID-19.
Image: Hydroxychloroquine freebase molecule – https://en.wikipedia.org/wiki/Hydroxychloroquine
The NCI Board of Scientific Advisors has approved concepts for an RFA and an RFP to support research in serological testing.
The plan presented to BSA May 12 is intended to distribute $306 million in new money the institute received “to develop, validate, improve, and implement serological testing and associated technologies” under the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139).
